Novo Nordisk: Q1 EPS up 29%

(CercleFinance.com) - Novo Nordisk reports Q1 2024 EPS that is up 29% to 5.
68 DKK, with operating profit up 27% (+30% at constant exchange rates) to over 31.8bn DKK.

The Danish pharmaceutical company, which specializes in the treatment of diabetes and obesity, saw sales rise by 22% (+24% at CER) to over 65.3bn DKK, notably supported by the US market.

For FY 2024, at CER, sales growth is now expected between 19% and 27%, with operating profit up by 22% to 30%, target ranges that are up one point on previous ones.


Copyright (c) 2024 CercleFinance.com. All rights reserved.